AIMS/HYPOTHESIS: Insulin resistance in skeletal muscle is linked to mitochondrial dysfunction in obesity and type 2 diabetes. Emerging evidence indicates that reversible phosphorylation regulates oxidative phosphorylation (OxPhos) proteins. The aim of this study was to identify and quantify site-specific phosphorylation of the catalytic beta subunit of ATP synthase (ATPsyn-beta) and determine protein abundance of ATPsyn-beta and other OxPhos components in skeletal muscle from healthy and insulin-resistant individuals. METHODS: Skeletal muscle biopsies were obtained from lean, healthy, obese, non-diabetic and type 2 diabetic volunteers (each group n = 10) for immunoblotting of proteins, and hypothesis-driven identification and quantification of phosphorylation sites on ATPsyn-beta using targeted nanospray tandem mass spectrometry. Volunteers were metabolically characterised by euglycaemic-hyperinsulinaemic clamps. RESULTS: Seven phosphorylation sites were identified on ATPsyn-beta purified from human skeletal muscle. Obese individuals with and without type 2 diabetes were characterised by impaired insulin-stimulated glucose disposal rates, and showed a approximately 30% higher phosphorylation of ATPsyn-beta at Tyr361 and Thr213 (within the nucleotide-binding region of ATP synthase) as well as a coordinated downregulation of ATPsyn-beta protein and other OxPhos components. Insulin increased Tyr361 phosphorylation of ATPsyn-beta by approximately 50% in lean and healthy, but not insulin-resistant, individuals. CONCLUSIONS/ INTERPRETATION: These data demonstrate that ATPsyn-beta is phosphorylated at multiple sites in human skeletal muscle, and suggest that abnormal site-specific phosphorylation of ATPsyn-beta together with reduced content of OxPhos proteins contributes to mitochondrial dysfunction in insulin resistance. Further characterisation of phosphorylation of ATPsyn-beta may offer novel targets of treatment in human diseases with mitochondrial dysfunction, such as diabetes.
AIMS/HYPOTHESIS: Insulin resistance in skeletal muscle is linked to mitochondrial dysfunction in obesity and type 2 diabetes. Emerging evidence indicates that reversible phosphorylation regulates oxidative phosphorylation (OxPhos) proteins. The aim of this study was to identify and quantify site-specific phosphorylation of the catalytic beta subunit of ATP synthase (ATPsyn-beta) and determine protein abundance of ATPsyn-beta and other OxPhos components in skeletal muscle from healthy and insulin-resistant individuals. METHODS: Skeletal muscle biopsies were obtained from lean, healthy, obese, non-diabetic and type 2 diabetic volunteers (each group n = 10) for immunoblotting of proteins, and hypothesis-driven identification and quantification of phosphorylation sites on ATPsyn-beta using targeted nanospray tandem mass spectrometry. Volunteers were metabolically characterised by euglycaemic-hyperinsulinaemic clamps. RESULTS: Seven phosphorylation sites were identified on ATPsyn-beta purified from human skeletal muscle. Obese individuals with and without type 2 diabetes were characterised by impaired insulin-stimulated glucose disposal rates, and showed a approximately 30% higher phosphorylation of ATPsyn-beta at Tyr361 and Thr213 (within the nucleotide-binding region of ATP synthase) as well as a coordinated downregulation of ATPsyn-beta protein and other OxPhos components. Insulin increased Tyr361 phosphorylation of ATPsyn-beta by approximately 50% in lean and healthy, but not insulin-resistant, individuals. CONCLUSIONS/ INTERPRETATION: These data demonstrate that ATPsyn-beta is phosphorylated at multiple sites in human skeletal muscle, and suggest that abnormal site-specific phosphorylation of ATPsyn-beta together with reduced content of OxPhos proteins contributes to mitochondrial dysfunction in insulin resistance. Further characterisation of phosphorylation of ATPsyn-beta may offer novel targets of treatment in human diseases with mitochondrial dysfunction, such as diabetes.
Authors: Zhengping Yi; Moulun Luo; Lawrence J Mandarino; Sara M Reyna; Christopher A Carroll; Susan T Weintraub Journal: J Am Soc Mass Spectrom Date: 2006-02-28 Impact factor: 3.109
Authors: José M Cuezva; Maryla Krajewska; Miguel López de Heredia; Stanislaw Krajewski; Gema Santamaría; Hoguen Kim; Juan M Zapata; Hiroyuki Marusawa; Margarita Chamorro; John C Reed Journal: Cancer Res Date: 2002-11-15 Impact factor: 12.701
Authors: Kurt Højlund; Krzysztof Wrzesinski; Peter Mose Larsen; Stephen J Fey; Peter Roepstorff; Aase Handberg; Flemming Dela; Jørgen Vinten; James G McCormack; Christine Reynet; Henning Beck-Nielsen Journal: J Biol Chem Date: 2003-01-16 Impact factor: 5.157
Authors: Kurt Højlund; Peter Staehr; Bo Falck Hansen; Kevin A Green; D Grahame Hardie; Erik A Richter; Henning Beck-Nielsen; Jørgen F P Wojtaszewski Journal: Diabetes Date: 2003-06 Impact factor: 9.461
Authors: Fernando López-Ríos; María Sánchez-Aragó; Elena García-García; Alvaro D Ortega; José R Berrendero; Francisco Pozo-Rodríguez; Angel López-Encuentra; Claudio Ballestín; José M Cuezva Journal: Cancer Res Date: 2007-10-01 Impact factor: 12.701
Authors: Craig S Stump; Kevin R Short; Maureen L Bigelow; Jill M Schimke; K Sreekumaran Nair Journal: Proc Natl Acad Sci U S A Date: 2003-06-13 Impact factor: 11.205
Authors: Laura Formentini; Alexander J Ryan; Manuel Gálvez-Santisteban; Leslie Carter; Pam Taub; John D Lapek; David J Gonzalez; Francisco Villarreal; Theodore P Ciaraldi; José M Cuezva; Robert R Henry Journal: Diabetologia Date: 2017-08-02 Impact factor: 10.122
Authors: J Giebelstein; G Poschmann; K Højlund; W Schechinger; J W Dietrich; K Levin; H Beck-Nielsen; K Podwojski; K Stühler; H E Meyer; H H Klein Journal: Diabetologia Date: 2012-01-27 Impact factor: 10.122